Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Peripheral Blood Stem Cell Transplantation 23fludarabine phosphate 20Cyclophosphamide 18Mycophenolic Acid 16Whole-Body Irradiation 15Cyclosporine 15Busulfan 12Tacrolimus 11Methotrexate 10Antilymphocyte Serum 9Radiotherapy 8Melphalan 8Etoposide 8pembrolizumab 7Methylprednisolone 6Filgrastim 6Sirolimus 4Prednisone 4Nivolumab 4sargramostim 3Vincristine 3Transplantation 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3Amplified Fragment Length Polymorphism Analysis 3mogamulizumab 2merphos 2bempegaldesleukin 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Aclarubicin × Dermatologic × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡